Spondyloarthritis & psoriatic arthritis

Use of risk chart algorithms for the identification of psoriatic arthritis patients at high risk for cardiovascular disease: findings derived from the project CARMA cohort after a 7.5-year follow-up period

RMD OpenPublished Prospective cohort study

Authors' conclusion

Risk chart algorithms are very useful for discriminating PsA at low and high CV risk. An integrated model featuring QRISK3 and SCORE2 yielded the optimal synergy of QRISK3's discrimination ability and SCORE2's calibration accuracy.

Study context

Population
Psoriatic arthritis (PsA) patients with no history of cardiovascular (CV) events at baseline, Spanish prospective CARMA project, rheumatology outpatient clinics at tertiary centres
Participants
669 patients
Exposure
Four CV risk algorithms: SCORE, mSCORE EULAR 2015/2016, SCORE2 and QRISK3
Outcome
Predictive value of CV risk algorithms for CV events
Follow-up
7.5 years
Methodological detailsretrospective analysis of baseline data, tertiary centres, 7.5-year follow-up
  • Retrospective analysis of baseline data
  • Tertiary centres
  • 7.5-year follow-up

Main finding

As reported in the abstract

CV events and performance of CV risk algorithms
CV events over 4790 years of follow-up
34
Linearised CV event rate per 1000 person-years
7.10 (95% CI 4.92 to 9.92)
All four CV risk scales significantly associated with CV events
p<0.001
QRISK3 + SCORE2 combination, Akaike information criterion (lowest; best predictive model)
411.15
QRISK3 + SCORE2 combination, Bayesian information criterion (lowest)
420.10

Observational data: associations, not effects.

Original publication

Use of risk chart algorithms for the identification of psoriatic arthritis patients at high risk for cardiovascular disease: findings derived from the project CARMA cohort after a 7.5-year follow-up period. RMD Open. Published 17 April 2024. doi:10.1136/rmdopen-2024-004207

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.